Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | |||||||||||||
Title | Imlygic (talimogene laherparepvec) FDA Drug Label | ||||||||||||
|
|||||||||||||
URL | https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/imlygic-talimogene-laherparepvec | ||||||||||||
Abstract Text |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Talimogene laherparepvec | Talimogene laherparepvec | 0 | 13 |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Talimogene laherparepvec | Imlygic | OncoVEX GM-CSF|T-VEC | Imlygic (talimogene laherparepvec) is a GM-CSF expressing herpes simplex type-1 virus (HSV-1) that selectively infects and lyses tumor cells, and potentially induces a cytotoxic immune response against tumor cells (PMID: 25777572). Imlygic (talimogene laherparepvec) is FDA approved for use in patients with recurrent melanoma (FDA.gov). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|